ClinicalTrials.gg
CompletedNCT04297449Updated Sep 16, 2021

Prospective 2-year Data Collection of the First 10 Patients After Ankle Spacer Implantation

An observational study in Osteochondritis Dissecans, sponsored by Hannover Medical School. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by Hannover Medical School · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
8
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Osteochondral defects (OCD) of the talus are pathologic lesions of the talar cartilage and its subchondral bone and might severely deteriorate the quality of life. For the treatment of multiple and/or large talar OCDs and in patients with failed previous surgical treatment the Ankle Spacer was developed. Six patients are included in a prospective clinical and radiological study with a follow-up of two years.

Read the detailed description

One surgeon in the investigator's center implanted 10 Ankle Spacers between April 2018 and October 2020. The average age was 41.7 years (20 - 70 years). All patients get a standard followed-up at 6 weeks, 12 weeks. After the first four patients, all following patients are enrolled in a prospective study and where followed up after 1 and 2 years additionally. The American Orthopaedic Foot and Ankle Society (AOFAS) Score, the Foot and Ankle Outcome Score (FAOS), the European Foot and Ankle Score (EFAS), the Visual Analogue Scale (VAS) for pain are collected. Radiographic parameters such as implant loosening, cystic changes, lateral/medial prominence of the implant, congruency to the talar rounding, progression of osteoarthritis or bone ware of the tibia plafond are recorded. The Ankle Spacer is a one-piece implant system that replaces the articulating upper talus surface of the tibio-talar joint, and offers several implant sizes in order to fit to the different talus sizes. It is anatomically designed to the native upper talus surface to provide an optimal fit to the distal articular surface. It has a rough titanium plasma spray (TPS) coated under surface with two posts and spikes for implant fixation. The rough surface enables secondary fixation by means of bone ingrowth and the spikes at the posterior part of the prosthesis allowing for optimal adherence of the implant and for minimal iatrogenic damage upon fixation. By these means, the anatomical situation and the natural congruency of the ankle joint are mirrored to an optimal extent.

02

Conditions studied

  • Osteochondritis Dissecans

Keywords

  • Osteochondral defects (OCD) of the talus
  • Ankle Spacer
  • osteoarthritis of the ankle joint
03

In context

Osteochondritis Dissecans

30 studies on the registry are indexed under Osteochondritis Dissecans; 7 are open to participants now.

This study's enrollment of 8 is below the median of 130 across 12 observational studies indexed under Osteochondritis Dissecans.

Browse Osteochondritis Dissecans studies →

Lead sponsor

Hannover Medical School is the lead sponsor of 202 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The average age is 41.7 years (20 - 70 years). Patients with multiple and/or large talar osteochondral defects (OCD) and patients with failed previous surgical treatment for OCD or osteoarthritis of the talus with up to grade two (Kellgren-Lawrence-Score) osteoarthritis on the tibial site are included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women and men aged 18-80 years
  • Indication for implantation of the ankle spacer

Exclusion criteria

Exclusion Criteria:

  • Florid infections
  • Relevant circulatory disorders on the affected leg
  • Malposition of the OSG (upper ankle Joint) greater than 5 ° varus or valgus
  • Fractures of the OSG or near the ankle that were less than 6 months ago
  • Obesity with a greater than 30 kg / m2
  • Known insulin-dependent diabetes mellitus
  • Known rheumatoid Arthritis
  • Osteoarthritis of the OSG II ° or higher according to Kellgren / Lawrence
  • Deformation of the OSG, which does not allow implantation of the ankle spacer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
8 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prospective 2-year Data Collection of the First 10 Patients after Ankle Spacer Implantation

    Prospective 2-year Data Collection of the First 10 Patients after Ankle Spacer Implantation

    Time frame: 2 Years

07

Study locations

1 site
  • Orthopädische Klinik der Medizinischen Hochschule Hannover im DIAKOVERE Annastift
    Hanover, Niedersachsen 30625, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Jan 2021, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2020
First posted
Mar 5, 2020
StartActual
Jan 18, 2019
Primary completionActual
Jan 19, 2021
CompletionActual
Sep 3, 2021
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04297449
Responsible party
Sponsor
First posted
Mar 5, 2020
Start date
Jan 18, 2019
Primary completion
Jan 19, 2021
Completion
Sep 3, 2021
Last update
Sep 16, 2021

Study contacts

Matthias Lerch, PD Dr.
principal investigator · Orthopädische Klinik der Medizinischen Hochschule Hannover im DIAKOVERE Annastift

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion